Hepatosplenic T cell lymphoma in inflammatory bowel disease

Shale, Matthew; Kanfer, Ed; Panaccione, Remo; Ghosh, Subrata
December 2008
Gut;Dec2008, Vol. 57 Issue 12, p1639
Academic Journal
The article discusses the enhancement of lymphoma in inflammatory bowel disease (IBD). It mentions that thiopurine therapy has possibility to cause risk of lynmphoma. The experts state the appearance of hepatosplenic T cell lymphoma (HSTCL) in the patients of IBD who are displayed with anti-tumour necrosis factor (TNF). According to the authors, professionals continue to look for treating HSTCL.


Related Articles

  • Control of matrix metalloproteinase production in human intestinal fibroblasts by interleukin 21. Monteleone, G.; Caruso, R.; Fina, D.; Peluso, I.; Gioia, V.; Stolfi, C.; Fantini, M. C.; Caprioli, F.; Tersigni, R.; Alessandroni, L.; MacDonald, T. T.; Pallone, F. // Gut;Dec2006, Vol. 55 Issue 12, p1774 

    Background: T cell-mediated immunity plays a central part in the pathogenesis of tissue damage in inflammatory bowel disease (IBD). The mechanism by which T cells mediate tissue damage during IBD remains unclear, but evidence indicates that T cell-derived cytokines stimulate fibroblasts to...

  • Dysregulated LIGHT expression on T cells mediates intestinal inflammation and contributes to IgA nephropathy. Jing Wang; Anders, Robert A.; Qiang Wu; Dacheng Peng; Cho, Judy H.; Sun, Yonglian; Karaliukas, Reda; Hyung-Sik Kang; Turner, Jerrold R.; Yang-Xin Fu // Journal of Clinical Investigation;Mar2004, Vol. 113 Issue 6, p826 

    Whether and how T cells contribute to the pathogenesis of immunoglobulin A nephropathy (IgAN) has not been well defined. Here, we explore a murine model that spontaneously develops T cell-mediated intestinal inflammation accompanied by pathological features similar to those of human IgAN....

  • Stem Cells in Inflammatory Bowel Disease: New Potential Therapeutic Target. In Hwan Song; Byung Ik Jang // Intestinal Research;2013, Vol. 11 Issue 2, p79 

    Understanding of the pathophysiology of inflammatory bowel disease (IBD) is constantly evolving and, recently, a number of biologic agents that selectively target specific molecules or pathways to correct the imbalance of the gut immune system have been developed. Among them, an antibody to...

  • Rate and Predictors of Mucosal Healing in Patients with Inflammatory Bowel Disease Treated with Anti-TNF-Alpha Antibodies. Beigel, Florian; Deml, Matthias; Schnitzler, Fabian; Breiteneicher, Simone; Göke, Burkhard; Ochsenkühn, Thomas; Brand, Stephan // PLoS ONE;Jun2014, Vol. 9 Issue 6, p1 

    Objective: Mucosal healing (MH) is an important treatment goal in patients with inflammatory bowel disease (IBD), but factors predicting MH under medical therapy are largely unknown. In this study, we aimed to characterize predictive factors for MH in anti-TNF-alpha antibody-treated IBD...

  • Recommendations on the use of anti-TNFs in adults with Inflammatory Bowel Disease. Watermeyer, G.; Epstein, D.; Kassianides, C. // South African Gastroenterology Review;Nov2015, Vol. 13 Issue 3, p21 

    The article focuses on findings of a study realted to recommendations on the use of anti-TNFs in adults with inflammatory bowel disease (IBD). Topics include definitions of terms like Corticosteroid resistance, and Primary Biologic failure; Induction of remission in luminal Crohn's disease; the...

  • Effects of Antioxidant Polyphenols on TNF-Alpha-Related Diseases. Kawaguchi, Kiichiro; Matsumoto, Tsukasa; Kumazawa, Yoshio // Current Topics in Medicinal Chemistry;Jul2011, Vol. 11 Issue 14, p1767 

    Oxidative stress and inflammatory responses sustained for a long period of time cause many diseases. A proinflammatory cytokine, tumor necrosis factor a (TNF-a), plays a pivotal role in the pathogenesis of chronic and autoimmune diseases. The present review, supplemented by hitherto unpublished...

  • Risks and benefits of combining immunosuppressives and biological agents in inflammatory bowel disease: is the synergy worth the risk? Hanauer, Stephen B. // Gut;Sep2007, Vol. 56 Issue 9, p1181 

    Since the introduction of infliximab to treat Crohn's disease, combination therapy, with immunosuppressants has reduced immunogenicity, without impacting efficacy. The availability of novel anti-TNF agents and potential combined toxicities question the risk/benefit of combination therapies.

  • The tale of TL1A in inflammation. Hsu, H.; Viney, J. L. // Mucosal Immunology (1933-0219);Jul2011, Vol. 4 Issue 4, p368 

    TL1A (also known as TNFSF15) is a tumor necrosis factor (TNF) family member expressed by monocytes, macrophages, dendritic cells (DCs), synovial fibroblasts, and endothelial cells in response to stimulation by cytokines, immune complexes, and microorganisms.1, 2, 3, 4, 5 Its cell surface...

  • GITR modulates innate and adaptive mucosal immunity during the development of experimental colitis in mice. Santucci, L.; Agostini, M.; Bruscoli, S.; Mencarelli, A.; Ronchetti, S.; Ayroldi, E.; Morelli, A.; Baldoni, M.; Riccardi, C. // Gut;Jan2007, Vol. 56 Issue 1, p52 

    Background: Uncontrolled T cell activation and abnormal function of the innate immune system against normal enteric bacterial flora play a critical part in the pathogenesis of inflammatory bowel disease (IBD). Therefore, pharmacological strategies directed to restore the normal responsiveness of...


Read the Article


Sign out of this library

Other Topics